There are drugs should be avoided despite authorisation by Agencies.

Can we justify drugs with no proven efficacy or relevant clinical outcomes?

1. Prescrire’s (non-profit organization, IF:0.18) publishes an annual review of drugs to avoid.
2. They identified 105 drugs that cover studies between 2010-2019.
3. They identified 105 drugs that cover studies between 2010-2019.
4. They identified 105 drugs that cover studies between 2010-2019.
5. Better harm-benefit balance drugs are available in most of cases.

To analyse and check how strong is a pharmacotherapeutic guide (PG) according to 2020 Prescrire’s review.

We evaluated the 2020 annual review of drugs to avoid of Prescrire’s and the concordance with a PG of a II-level-hospital and the impact of use and cost vs alternatives available between January-August-2020.

Information were recollected of the Farmatools® software of hospital pharmacy management and the Prescrire’s review.

Data recollected:
- Drugs and Prescrire’s alternative proposal include in the PG.
- Use [Defined Daily Dose (DDD)] and cost of the drugs of Prescrire’s include in the PG and his alternatives and the entire PG.

82 (78.1%) had not presence in the PG – 60 had better harm benefit alternative – 58 (96.7%) in our PG

105 drugs to avoid

23 (21.9%) had presence in the PG – 15 with guarantee better choice – 15 (100%) in our PG

- 2 (trabectedin y vinflunina)
- 1 (Teriflunomide)

The global PG use was around 14.000.000€

Our study shows our PG is well adapted according to Prescrire’s recommendations.

Drugs to avoid presence is low, and the majority because their use is well established in the clinical practice or are reserve for very specific situations. The global impact (without Teriflunomide) in total cost and use is worthless.

Our next step is to reevaluate the results and made a better PG, special focus in Teriflunomide (currently has a strong follow-up) and minimize the use of those essential for the physician in very specific situations.

It is possible to conclude that our PG, develop by hospital pharmacists in multidisciplinary team, is a guarantee of quality, security and efficiency matter.

Correspondence to:
Jaime Fernández-Bravo Rodrigo
jaimefernandezbravorodrigo@gmail.com

REFERENCES